Study S000890

Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07597018
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 234
Start: 2026-05-18
Primary completion: 2027-05-28
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:Cagrilintide D; DRUG:Cagrilintide B and placebo semaglutide I
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1314-9337; OTHER:2025-521384-12; NIH:2025

Registered primary outcomes

AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c. [Day 113 (pre-dose) to Day 120 (post-dose)]
Cmax,ss: maximum concentration of total cagrilintide at steady state after 5th dosing of cagrilintide s.c. [Day 113 (pre-dose) to Day 120 (post-dose)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.